Opko Health, Inc. (OPK)
AI stock analysis · as of Jul 29, 2026
Loading microstructure…
OPKO Health is a small-cap healthcare company straddling a shrinking diagnostics business (post-BioReference divestitures to Labcorp) and an early-stage pharma/pipeline story anchored by NGENLA royalties from Pfizer and ModeX's multispecific antibody platform (partnered with Merck and Regeneron). The core investment question is whether NGENLA royalty growth plus ModeX pipeline optionality can offset persistent operating losses, negative FCF, and revenue declines from divested diagnostic assets before liquidity or dilution pressures force capital actions.
valuationExpensive on fundamentals: P/S of 2.1x on declining revenue, negative EV/EBITDA (-16.9x), forward P/E of -6.3x, and a PEG of 93.6x — the stock trades as a pipeline option, not on current cash flows.
This analysis is from Jul 29, 2026. Want the latest on OPK, plus the ability to generate fresh research on demand?
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.
Bull case
- · NGENLA is being commercialized by Pfizer across 50+ markets with a tiered gross-profit share, and potential SGA label expansion could inflect royalty economics without OPKO bearing commercial costs
- · High-quality partnerships de-risk the pipeline: Regeneron collaboration signed Oct 2025 with upfront payment, Merck EBV vaccine dosed first Phase 1 patient Jan 2025, plus BARDA-funded infectious disease programs
- · Q2 2026 print beat on revenue with narrowing losses, driving a ~33% single-day rally to a 52-week high — suggests fundamentals may be inflecting
- · Balance sheet still workable: $369M cash roughly matches $396M debt, and the Labcorp divestiture proceeds (up to $462.5M aggregate) fund the pharma pivot
- · Insider alignment is unusually high at ~49.9% insider ownership (Frost-led), and no net insider selling over the past 180 days
- · Short interest at 7.94% of float with 10.8 days-to-cover creates squeeze potential on continued positive pipeline or earnings surprises
Bear case
- · Revenue is structurally shrinking: FY2025 revenue of $607M is down ~15% YoY and down ~30% vs FY2023 ($863M) as BioReference assets were sold
- · Sustained unprofitability: FY2025 net loss of $226M (net margin -37%), FCF of -$191M, and forward P/E of -6.3x indicate no near-term path to profitability
- · Debt-to-equity of 33x and a complex convertible stack (2025, 2029, 2044 notes plus an April 2025 exchange) create refinancing/dilution risk
- · ModeX pipeline is entirely Phase 1 — binary clinical risk with goodwill/intangible impairment exposure if programs fail
- · Key-man risk explicitly tied to Chairman/CEO Dr. Phillip Frost, plus an active Corporate Integrity Agreement with HHS OIG since 2022
- · GuruFocus flags stock as ~19% overvalued post-rally; PEG of 93.6x and P/S of 2.1x on declining revenue are hard to justify on fundamentals alone
Catalysts
- · Next earnings on 2026-07-27 — will test whether Q2 beat momentum is sustainable
- · ModeX Phase 1 readouts across MDX2001 (solid tumors), MDX2003 (heme), B-cell lymphoma, and COVID prevention programs
- · NGENLA SGA label expansion decision and continued geographic rollout by Pfizer
- · Rayaldee China regulatory decision and further European launches
- · Additional Regeneron/Merck milestone payments tied to pipeline progress
- · Elevated short interest (7.94% float, 10.8 days-to-cover) sets up potential squeeze on positive surprises
Key risks
- · Convertible debt refinancing and dilution if operating losses continue and cash burn (~$191M FCF loss) is not curtailed
- · Phase 1 clinical failure in ModeX pipeline would impair valuation of the pharma-pivot thesis
- · Continued revenue erosion from residual BioReference operations facing reimbursement pressure
- · Overreliance on Pfizer execution for NGENLA — OPKO has no direct commercial control
- · Regulatory/compliance risk under the ongoing HHS OIG Corporate Integrity Agreement
What to watch
- · Q2 2026 earnings on 2026-07-27 — revenue trajectory and cash burn
- · ModeX Phase 1 interim data disclosures in solid tumors, heme, and B-cell lymphoma
- · NGENLA royalty disclosure trends and any SGA label expansion news
- · Convertible note activity — any new exchanges, tenders, or refinancing announcements
- · Short interest evolution given 10.8 days-to-cover and post-earnings momentum
- · Technical level: 52-week high near $1.61 — sustained breakout vs. failure back into the prior range
Key metrics
Price target rationale
Base case applies ~3x P/S on ~$650M forward revenue plus modest pipeline option value, netting debt — landing near $2. Bull case assumes NGENLA milestone acceleration and positive Phase 1 data supporting a re-rating toward the analyst mean. Bear case reflects continued revenue decline, cash burn, and dilutive refinancing bringing the stock back toward book value (~$1.60) and below to ~$1.
On Wall Street's view (mixed): The $4.38 mean target implies ~165% upside and looks aggressive relative to current burn and revenue decline, but is defensible if you assign meaningful probability to NGENLA royalty ramp plus ModeX partnership milestones. I'd anchor closer to the low end of the street range given execution risk.
Latest filing (10-K)
OPKO is a shrinking-diagnostics, growing-pharma story betting on ModeX's multispecific antibody pipeline and NGENLA royalties to replace the BioReference revenue it sold to Labcorp, while carrying a complex convertible debt load and a long history of losses.
OPKO Health is a diversified healthcare company operating two segments: pharmaceuticals and diagnostics. The pharmaceutical segment commercializes NGENLA (somatrogon, a once-weekly growth hormone partnered with Pfizer), Rayaldee (an FDA-approved CKD/vitamin D treatment), and a pipeline of multispecific antibodies and vaccines through subsidiary ModeX Therapeutics; it also runs established pharma platforms in Spain, Ireland, Chile, and Mexico. The diagnostics segment operates BioReference Health, a specialty clinical laboratory focused on the New York/New Jersey region and a national urology franchise including the proprietary 4Kscore prostate cancer test, following two divestitures of non-core lab assets in 2024-2025 for aggregate consideration of up to $462.5 million.
What the news says · bullish
OPKO Health delivered a strong Q2 2026 earnings beat on revenues while shrinking losses, triggering a dramatic ~33% single-day surge to a 52-week high. The dominant storyline is a combination of better-than-expected financials and pipeline progress, including the initiation of Phase 1 trials in B-Cell Lymphoma and COVID prevention. Coverage is relatively concentrated around a single earnings event, so the enthusiasm may partly reflect short-term momentum rather than a fundamental re-rating. One notable counterpoint is GuruFocus flagging the stock as ~19% overvalued on its GF Value metric, suggesting the post-earnings pop may have stretched the valuation. Insider share withholdings for taxes are routine and not a red flag, but investors should watch whether the pipeline catalysts and revenue trajectory can sustain the move.
This analysis is from Jul 29, 2026. Markets move. Get the current read on OPK and generate fresh AI research on any ticker.
Every call we make is tracked publicly against what the stock actually did. See the track record →
One free AI report every day. No card required.